...
首页> 外文期刊>Drug delivery. >Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics
【24h】

Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics

机译:杂交的内部多孔聚(乳酸 - 共乙酸)微球作为长效药物递送系统,具有改善的释放特性

获取原文

摘要

The glucagon-like peptide-1 receptor agonist exenatide (EXT) is an effective treatment for type 2 diabetes. However, this peptide has a short biological half-life and the delayed release characteristic of current formulations limit its clinical application. Herein, we prepared EXT-loaded inside-porous poly(d,l-lactic-co-glycolic acid (PLGA) microspheres with outside layers (EXT-PMS) using a Wsub1/sub/O/Wsub2/sub emulsion method with a microfluidic technique and its fabrication and formulation conditions were systematically investigated. In vitro dissolution experiments showed that the PLGA concentration, proportion of drug and oil phase, and the number and size of pores strongly affected the release behaviors of EXT-PMS. In vitro , the optimized EXT-PMS with large internal pores exhibited rapid and stable release without a lag phase. In a rat model, subcutaneous administration of the product yielded plasma concentrations of EXT that was sustained for 30?days with low burst and no delayed-release effect. The preparation of inside-porous microspheres is lighting up the development of long-acting drug delivery systems for other drugs with favorable release characteristics.
机译:胰高血糖素肽-1受体激动剂exenatide(ext)是2型糖尿病的有效处理。然而,该肽具有短的生物半衰期,并且电流配方的延迟释放特性限制了其临床应用。在此,使用W 1 / O / W <,我们使用W 1 / o / w 2 乳液方法。体外溶解实验表明,PLGA浓度,药物和油相比例,以及孔隙的数量和尺寸强烈影响ext-pms的释放行为。体外,具有大型内部孔隙的优化的ext-pm,没有滞后阶段的快速稳定释放。在大鼠模型中,产物的皮下施用液体的血浆浓度为30?爆发的几天和没有延迟释放效果。内部多孔微球的制备正在照亮用于其他药物具有良好释放特性的其他药物的长效药物递送系统的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号